Europe
Amgen and AstraZeneca announced that their Phase III NAVIGATOR trial of Tezepelumab hit the primary endpoint in severe asthma.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for November 10, 2020.
IntraBio lauched a Phase II expansion study for IB1001 (N-Acetyl-L-Leucine) soon after announcing positive results from the initial “parent” multinational trials for Niemann-Pick disease Type C (NPC).
Calliditas said Nefecon hit its primary endpoint by demonstrating a statistically significant reduction in urine protein creatinine ratio, UPCR or proteinuria, after nine months of treatment.
The pre-specified interim data analysis indicated that the Cabotegravir hit the primary objective of superiority compared to the current standard of care for women.
They caution that as more data is accumulated and analyzed, the efficacy percentage may shift. Nonetheless, it’s extremely promising and there were no serious safety signals.
It was relatively quiet in terms of COVID-19-related clinical trials, but there was still quite a bit of news for trials involving other indications. Here’s a look.
A multi-institutional research team has developed a nasal spray that effectively blocks absorption of the SARS-CoV-2 virus in ferrets with direct contact to infected animals.
This morning, the Swiss pharma giant announced Ilaris plus standard of care did not demonstrate a significantly greater chance of survival for patients without the need for invasive mechanical ventilation, compared with placebo plus the standard of care.
Shares of Endo International are up more than 5% after the company announced positive earnings Thursday and also announced a new restructuring plan.
PRESS RELEASES